2. Immunology/Inflammation
  3. Galectin Tim3
  4. HFB200901

HFB200901 is a galectin LGALS9 inhibitor and immunostimulant that can be used in studies related to pancreatic adenocarcinoma, pancreatic intraepithelial neoplasia, KRASG12C-mutant colon cancer, and prostate cancer. HFB200901 disrupts the LGALS9/TIM-3 axis, while blocking the internalization and vacuolization of recombinant LGALS9. HFB200901 reduces the proportion of regulatory T cells (Treg) and enhances dendritic cell activation, thereby inducing polyfunctional and memory CD8+ T cell responses. HFB200901 inhibits the progression of pancreatic neoplastic lesions and effectively improves the efficacy of PSMA-based vaccination.

For research use only. We do not sell to patients.

HFB200901

HFB200901 Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

HFB200901 Related Antibodies

Top Publications Citing Use of Products

View All Galectin Isoform Specific Products:

View All Isoforms
Galectin-1 Galectin-3 Galectin-4 Galectin-8

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

HFB200901 is a galectin LGALS9 inhibitor and immunostimulant that can be used in studies related to pancreatic adenocarcinoma, pancreatic intraepithelial neoplasia, KRASG12C-mutant colon cancer, and prostate cancer. HFB200901 disrupts the LGALS9/TIM-3 axis, while blocking the internalization and vacuolization of recombinant LGALS9. HFB200901 reduces the proportion of regulatory T cells (Treg) and enhances dendritic cell activation, thereby inducing polyfunctional and memory CD8+ T cell responses. HFB200901 inhibits the progression of pancreatic neoplastic lesions and effectively improves the efficacy of PSMA-based vaccination[1][2][3][4].

Species Reactivity

Human
In Vitro

Anti-LGALS9 (HFB200901) (10 μg/mL; 1 h) potently inhibits rLGALS9-induced vacuolization in MDCK and DLD-1 KRASG12C mutant colon carcinoma cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

HFB200901 Related Antibodies
In Vivo

HFB200901 (20 µg-10 mg; s.c.; once weekly; 8 weeks) reduces pancreatic LGALS9 expression, lowers peripheral and infiltrating Treg levels, increases pancreatic-infiltrating CD4+ T cells, and limits PanIN progression in KC mice[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Pdx1-Cre; LSL-KrasG12D (KC) (2-month-old, transgenic model of early pancreatic carcinogenesis)[2]
Dosage: 20 µg; 10 mg
Administration: s.c.; once weekly; 8 weeks
Result: Reduced overall pancreatic LGALS9 expression (RFI: 2.06) compared to isotype control (RFI: 3.04).
Reduced LGALS9 expression in non-immune pancreatic cells (CD45−) (RFI: 2.06) compared to isotype control (RFI: 3.98).
Increased pancreatic-infiltrating CD4+ T cells to 20.1% compared to 12.33% for isotype control.
Reduced peripheral and pancreatic-infiltrating Treg levels.
Decreased total PanIN surface area; all untreated mice developed ADM and PanIN 1 with 5/6 having at least one PanIN Ib/II, while all treated mice had ADM or PanIN 1 with only 1/6 having one PanIN Ib/II.
Left peripheral CD4+ T cell levels unchanged (13.97% vs 13.99% for isotype).
Gene ID

3965  [NCBI]

Accession
Target

Galectin-9/LGALS9
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

HFB200901 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

HFB200901HFB 200901HFB-200901GalectinTim3T-Cell Immunoglobulin and Mucin Containing Protein-3CD366MDCKTreggalectin-9KRAS mutant colon carcinomaprostate cancerTIM-3pancreatic adenocarcinomaLGALS9pancreatic intraepithelial neoplasmDLD-1Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
HFB200901
Cat. No.:
HY-P992366
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.